Agency Receives Silver Award for Best Branded Website
COLUMBUS, OHIO, June 7, 2007 — Ignite Health, an inVentiv Health company (NASDAQ: VTIV), and a leading marketing agency that specializes in patient-centered medical advertising, was recently honored with a Silver Award at the seventh annual DTC National Awards ceremony. The awards competition, featured at the DTC National Conference in Washington, D.C., recognizes the most creative and breakthrough ideas across the pharmaceutical industry. Ignite won the award in the Best Branded Website category for a site it created for Eli Lilly and Company's Humalog.
The website, www.humalog.com, features a certified diabetes educator who guides online visitors through the site and addresses topics such as how to use insulin and control blood sugar. The educator also provides answers to commonly asked questions.
"We are thrilled to receive this national recognition," said Fabio Gratton, chief innovation officer for Ignite Health. "By creating online video messages that educate patients in a more personal way about issues relating to diabetes, we are helping Lilly to not only connect with the diabetes patient community, but also to empower patients to take positive steps to effectively manage their disease. To receive a DTC National Award for such work is truly an honor."
The June issue of DTC Perspectives magazine will feature full coverage of the DTC National Conference and will profile each of the DTC National Advertising award winners.
About Ignite Health
Headquartered in Irvine, California, Ignite Health is a new breed of advertising agency with a fresh approach to healthcare marketing and communications. By complementing highly focused print strategies with a wide range of tailored electronic strategies — from online advertising and patient education to custom-engineered games and simulations — the company helps clients meet their objectives with unparalleled effectiveness and efficiency. For more information, visit www.ignitehealth.com.
About inVentiv Health
inVentiv Health (NASDAQ: VTIV) is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. inVentiv Health currently works with over 200 unique pharmaceutical, biotech and life sciences clients, including all top 20 global pharmaceutical companies. For more information, visit www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.